NYSE · SYK
Stryker Corporation
$311.36+$7.36 (+2.42%)
Stryker Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.03% below the high.
Loading market information…
NYSE · MDT · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Medtronic Plc’s quoted price sits in the upper half of its reported 52-week range, 8.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Medtronic Plc’s forward annual dividend is $2.88 per share, paid quarterly. The forward yield is 2.97% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Medtronic Plc’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of $1.33. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Medtronic Plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 |
|---|
| May 21, 2025 |
| $1.62+2.53% vs estimate |
| $8.93B+1.23% vs estimate |
| Q3 2025 | Feb 18, 2025 | $1.39+2.21% vs estimate | $8.29B-0.42% vs estimate |
|---|
| Q2 2025 | Nov 19, 2024 | $1.26+0.8% vs estimate | $8.40B+1.55% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
51 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 15 contributors · Median target $97.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$311.36+$7.36 (+2.42%)
Stryker Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.03% below the high.
$42.69+$0.26 (+0.61%)
Boston Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 59.59% below the high.
$94.44+$2.66 (+2.9%)
Edwards Lifesciences Corporation’s quoted price sits in the upper half of its reported 52-week range, 1.92% below the high.
$27.12+$0.09 (+0.33%)
Koninklijke Philips N.V.’s quoted price sits in the lower half of its reported 52-week range, 18.9% below the high.
$97.47+$1.08 (+1.12%)
Zimmer Biomet Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.01% below the high.
$321.97+$3.66 (+1.15%)
Penumbra, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.16% below the high.
SEK 273.40+SEK 1.50 (+0.55%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
CN¥271.29-CN¥1.50 (-0.55%)
APT Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.55% below the high.
